Randomized Open Investigation Determining Steroid Dose
NCT04834375
Completed
Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against COVID-19 pneumonia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Northwell Health, New Hyde Park, New York
Conditions: Covid19
Register for Updates
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
NCT04276090
Terminated
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy. This study aims to test the safety of hepatic artery infusion pump placement, a standard surgical procedure, and intraarterial chemotherapy initiation with the standard medication floxuridine (FUDR), using the Medtronic Synchromed II pump combined with the Codman arterial catheter in patients with unresectable (not removable by surgery)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Bile Duct Neoplasms, Colorectal Neoplasms
Register for Updates
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients
NCT01749969
Completed
Primary Objectives: * To determine the maximum tolerated dose of SAR650984 (isatuximab) with lenalidomide and dexamethasone (LD) in patients with relapsed or refractory multiple myeloma. * Expansion Phase Only: To further evaluate preliminary evidence of antitumor activity (objective response rate \[ORR\]) of SAR650984 (isatuximab) in combination with LD using International Myeloma Working Group (IMWG) criteria. Secondary Objectives: * To evaluate the safety, including immunogenicity, of SAR6... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: Investigational Site Number 840004, San Francisco, California +4 locations
Conditions: Plasma Cell Myeloma
Register for Updates
The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1
NCT05143281
Completed
To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/05/2023
Locations: Grene Vision Group, Wichita, Kansas +1 locations
Conditions: Cataract
Register for Updates
Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19
NCT04860518
Terminated
This double-blinded, randomized study is being conducted to see if the investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a, can help patients recover more quickly from COVID-19 and prevent worsening of the condition. To understand if IV IFN beta-1a can help treat patients with COVID-19, this study drug will be compared to dexamethasone. Study subjects will be treated daily with IV IFN beta-1a 10 μg or IV dexamethasone for 6 consecutive days whi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2023
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Covid19
Register for Updates
Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.
NCT04501367
Recruiting
Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2023
Locations: Kovach Eye Institute, Elmhurst, Illinois
Conditions: Vitrectomy, Macular Pucker, Retinal Edema
Register for Updates
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
NCT04156828
Terminated
This phase I trial studies the best dose of copanlisib when given together with combination chemotherapy (R-GCD) in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or grade 3b follicular lymphoma that has come back (relapsed) after 1 prior line of therapy. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2023
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Register for Updates
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
NCT02623426
Completed
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out after 6 months of follow-up. The primary outcome is perce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Jules Stein Eye Institute, UCLA, Los Angeles, California +32 locations
Conditions: Uveitis, Macular Edema
Register for Updates
DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses
NCT04479748
Completed
The investigators seek to assess the effect of pre-operative and continued post-operative corticosteroid use on pain, patient preference, visual outcomes, and change in objective quantifiable biological parameters in patients undergoing bilateral cataract surgery with premium intraocular lens implantation with or without baseline ocular surface disease. Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BI... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Eye Associates of Vineland, Vineland, New Jersey
Conditions: Cataract
Register for Updates
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
NCT00002514
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
06/14/2023
Locations: Aurora Presbyterian Hospital, Aurora, Colorado +93 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00002878
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be killed. It is not yet known whether combination chemotherapy plus PSC 833 is more effective than combination chemotherapy alone in treating patients with relapsed or refractory multiple myeloma. PURPOSE: Randomized phase II... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2023
Locations: University of California San Diego Cancer Center, La Jolla, California +39 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
NCT00060398
Completed
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating anemia-related fatigue in patients with prostate cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see how well they work compared to epoetin alfa alone in... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2023
Locations: Memorial Medical Center Cancer Services, Modesto, California +139 locations
Conditions: Anemia, Fatigue, Prostate Cancer
Register for Updates